Please use this identifier to cite or link to this item: https://doi.org/10.21256/zhaw-23838
Publication type: Article in scientific journal
Type of review: Peer review (publication)
Title: Effect of the FDA black box suicidality warnings for antidepressants on suicide rates in the USA : signal or noise?
Authors: Plöderl, Martin
Hengartner, Michael Pascal
et. al: No
DOI: 10.1027/0227-5910/a000843
10.21256/zhaw-23838
Published in: Crisis
Volume(Issue): 44
Issue: 2
Page(s): 128
Pages to: 134
Issue Date: 17-Dec-2021
Publisher / Ed. Institution: Hogrefe
ISSN: 0227-5910
2151-2396
Language: English
Subjects: Suicide; Antidepressants; FDA; Black box warning; Adolescents
Subject (DDC): 615: Pharmacology and therapeutics
616.8: Neurology, diseases of nervous system
Abstract: Background: Some authors claimed that the US Food and Drug Administration (FDA) black box warning on treatment-emergent suicidality with antidepressants in adolescents (issued 2004) and young adults (issued 2006) led to an increase of suicides, based on the analyses of ecological data with debatable assumptions about putative changes in suicide rates. Aims: To explore if putative changes in suicide rates in adolescents and young adults at the time of the FDA warnings is a detectable signal in the data or compatible with random fluctuations. Method: We applied different changepoint analyses for adolescent and young adult suicide rates from 1981 to 2019 in the USA. Results: Changepoint analysis did not support a detrimental effect of the FDA black box warnings. The downward trend of suicides reversed several years after the warning in adolescents (2007–2009) and many years before in young adults (1999–2001). Limitations: Our analyses cannot rule out detrimental effects of the FDA warnings. However, even if there was such an effect, it was likely small and indistinguishable from random fluctuations in the available suicide data. Conclusion: There is no detectable change of trend in adolescent or young adult suicide rates in line with a detrimental effect of the FDA black box warnings on treatment-emergent suicidality.
URI: https://digitalcollection.zhaw.ch/handle/11475/23838
Fulltext version: Accepted version
License (according to publishing contract): Licence according to publishing contract
Departement: Applied Psychology
Organisational Unit: Psychological Institute (PI)
Appears in collections:Publikationen Angewandte Psychologie

Files in This Item:
File Description SizeFormat 
2021_Ploederl-Hengartner_Effect-of-the-FDA-black-box-suicidality-warnings_Accepted-version.pdfAccepted Version203.32 kBAdobe PDFThumbnail
View/Open
Show full item record
Plöderl, M., & Hengartner, M. P. (2021). Effect of the FDA black box suicidality warnings for antidepressants on suicide rates in the USA : signal or noise? Crisis, 44(2), 128–134. https://doi.org/10.1027/0227-5910/a000843
Plöderl, M. and Hengartner, M.P. (2021) ‘Effect of the FDA black box suicidality warnings for antidepressants on suicide rates in the USA : signal or noise?’, Crisis, 44(2), pp. 128–134. Available at: https://doi.org/10.1027/0227-5910/a000843.
M. Plöderl and M. P. Hengartner, “Effect of the FDA black box suicidality warnings for antidepressants on suicide rates in the USA : signal or noise?,” Crisis, vol. 44, no. 2, pp. 128–134, Dec. 2021, doi: 10.1027/0227-5910/a000843.
PLÖDERL, Martin und Michael Pascal HENGARTNER, 2021. Effect of the FDA black box suicidality warnings for antidepressants on suicide rates in the USA : signal or noise? Crisis. 17 Dezember 2021. Bd. 44, Nr. 2, S. 128–134. DOI 10.1027/0227-5910/a000843
Plöderl, Martin, and Michael Pascal Hengartner. 2021. “Effect of the FDA Black Box Suicidality Warnings for Antidepressants on Suicide Rates in the USA : Signal or Noise?” Crisis 44 (2): 128–34. https://doi.org/10.1027/0227-5910/a000843.
Plöderl, Martin, and Michael Pascal Hengartner. “Effect of the FDA Black Box Suicidality Warnings for Antidepressants on Suicide Rates in the USA : Signal or Noise?” Crisis, vol. 44, no. 2, Dec. 2021, pp. 128–34, https://doi.org/10.1027/0227-5910/a000843.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.